ArticleCureus2026
Primary Myeloid Sarcoma of the Breast Mimicking Carcinoma: Aberrant Expression of PAX5 and KMT2A::MLLT10 Fusion.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid sarcoma (MS) is a rare extramedullary tumor characterized by the proliferation of immature myeloid precursor cells. It most commonly occurs in association with acute myeloid leukemia, either at initial diagnosis or during disease progression. Breast involvement is exceedingly rare and represents a significant diagnostic challenge, as it can closely mimic more common breast malignancies, particularly carcinoma or lymphoma, frequently leading to misdiagnosis. We report the case of a 39-year-old woman who presented with two bilateral breast masses, initially suspected to be malignant based on clinical and radiological findings. Histopathological examination revealed a poorly differentiated malignant neoplasm composed of immature cells with eosinophilic cytoplasm and prominent nucleoli, diffusely infiltrating the mammary parenchyma. Immunohistochemical analysis demonstrated strong positivity for leukocyte common antigen (LCA), myeloperoxidase (MPO), and CD68, with focal expression of CD34 and CD117, supporting the diagnosis of primary bilateral breast MS; notably, aberrant expression of PAX5, a marker usually associated with B-cell lineage, constituted a potential diagnostic pitfall. Molecular analysis further identified a KMT2A::MLLT10 fusion, a rearrangement associated with monocytic differentiation and extramedullary involvement. Bone marrow biopsy showed no evidence of neoplastic infiltration. The patient was treated with combined chemotherapy and radiotherapy. This case highlights the diagnostic challenges posed by bilateral breast MS and underscores the critical role of histopathology, immunohistochemistry, and molecular studies in establishing an accurate diagnosis and guiding appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.